JNJ’s R&D strategy
Johnson & Johnson (JNJ) has made some changes to its R&D (research and development) strategy in its Medical Devices segment and shifted its R&D spending from incremental programs to high-potential and transformative initiatives. The company is focused on building an exciting product pipeline driven by innovation.
JNJ plans to launch 15–20 new products in 2018, 20–25 in 2019, and 40–50 in 2020 and beyond. These expectations exclude any additions to the pipeline as a result of acquisitions. In 2017, the company invested over $5 billion in acquisitions and partnerships.
JNJ’s product pipeline
In Johnson & Johnson’s interventional solutions business, it’s focused on advancing its technology in its attractive electrophysiology platform and investing in neurovascular innovation for the treatment of strokes.
In the surgery business, the company is working on the development of next-generation hemostats for more efficient bleeding management, smarter surgical devices, and advancement in digital surgery.
JNJ is advancing its orthopedics business through advanced technologies such as sensors, 3D printing, and digital technologies. In the eye health business, the company is continuously innovating in its leading contact lens business.
As per JNJ, its Medical Devices innovation pipeline is expected to yield new product sales of $7 billion by 2022, which reflects a rise of over 20% in its R&D productivity.
In the next article, we’ll discuss the commercial model for JNJ’s Medical Devices segment.